Challenges and Opportunities for Effective Cancer Immunotherapies
Anti-cancer immunotherapies have generated spectacular outcomes in the clinical environment and changed treatment schemes for cancer patients. Adoptive cell therapies (ACTs), including using autologous tumor-infiltrating lymphocytes and chimeric antigen receptor (CAR) T cells, and checkpoint blockad...
Saved in:
Other Authors: | , |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_98947 | ||
005 | 20230405 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20230405s2023 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-0365-6961-1 | ||
020 | |a 9783036569604 | ||
020 | |a 9783036569611 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-0365-6961-1 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a M |2 bicssc | |
100 | 1 | |a Kershaw, Michael |4 edt | |
700 | 1 | |a Slaney, Clare |4 edt | |
700 | 1 | |a Kershaw, Michael |4 oth | |
700 | 1 | |a Slaney, Clare |4 oth | |
245 | 1 | 0 | |a Challenges and Opportunities for Effective Cancer Immunotherapies |
260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
300 | |a 1 electronic resource (500 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a Anti-cancer immunotherapies have generated spectacular outcomes in the clinical environment and changed treatment schemes for cancer patients. Adoptive cell therapies (ACTs), including using autologous tumor-infiltrating lymphocytes and chimeric antigen receptor (CAR) T cells, and checkpoint blockades have emerged as the most effective treatments for certain cancers. The current challenge for cancer immunotherapies is that although some patients have benefited from the treatments, a number of cancers are resistant. The purpose of this Special Issue is to understand anti-cancer immunotherapy treatment resistance mechanisms and explore new options to provide opportunities for effective treatments. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Medicine |2 bicssc | |
653 | |a near infrared photoimmunotherapy | ||
653 | |a monoclonal antibodies | ||
653 | |a CD44 | ||
653 | |a interleukin-15 | ||
653 | |a cancer | ||
653 | |a antigen processing and presentation | ||
653 | |a cancer immunotherapy | ||
653 | |a cross-priming | ||
653 | |a immunogenicity | ||
653 | |a major histocompatibility complex | ||
653 | |a T lymphocyte | ||
653 | |a tumor-infiltrating lymphocytes | ||
653 | |a tumor microenvironment | ||
653 | |a tumor-specific antigen | ||
653 | |a pancreatic tumor | ||
653 | |a NK cell immunosurveillance | ||
653 | |a NKG2D | ||
653 | |a histon (de)acetylation | ||
653 | |a immunotherapy | ||
653 | |a PD-1 | ||
653 | |a microenvironment | ||
653 | |a CAR T cells | ||
653 | |a immune checkpoint inhibitors | ||
653 | |a cervical cancer | ||
653 | |a immune checkpoint inhibitor | ||
653 | |a pembrolizumab | ||
653 | |a recurrence | ||
653 | |a pattern-recognition receptors | ||
653 | |a toll-like receptors | ||
653 | |a intratumoural | ||
653 | |a tumour microenvironment | ||
653 | |a NKG2D ligands | ||
653 | |a NKG2D receptor | ||
653 | |a NK cells | ||
653 | |a immune evasion | ||
653 | |a convergent evolution | ||
653 | |a viruses | ||
653 | |a glioblastoma | ||
653 | |a model | ||
653 | |a animal model | ||
653 | |a preclinical | ||
653 | |a murine | ||
653 | |a immune response | ||
653 | |a GBM | ||
653 | |a newcastle disease virus | ||
653 | |a modulated electrohyperthermia | ||
653 | |a dendritic cell vaccination | ||
653 | |a clinical trial | ||
653 | |a individualized multimodal immunotherapy | ||
653 | |a CAR-T cell therapy | ||
653 | |a CD19 | ||
653 | |a clinical trials | ||
653 | |a CRS | ||
653 | |a toxicity | ||
653 | |a immunocyte membrane-coated nanoparticles | ||
653 | |a biomimicry | ||
653 | |a macrophage | ||
653 | |a T-cell | ||
653 | |a natural killer | ||
653 | |a dendritic cell | ||
653 | |a IL-12 family cytokines | ||
653 | |a anti-tumor immunity | ||
653 | |a STAT | ||
653 | |a B cell | ||
653 | |a T cell | ||
653 | |a antibody therapy | ||
653 | |a immuno-oncology | ||
653 | |a CD3-bispecific antibody | ||
653 | |a T-cell engager | ||
653 | |a solid tumors | ||
653 | |a on-target off-tumor toxicity | ||
653 | |a T-cell co-stimulation | ||
653 | |a tumor-associated antigens | ||
653 | |a chimeric antigen receptor | ||
653 | |a immune cell | ||
653 | |a endodomain | ||
653 | |a combination therapy | ||
653 | |a TNFα | ||
653 | |a adoptive cell therapy | ||
653 | |a monoclonal antibody | ||
653 | |a radiotherapy | ||
653 | |a local ablation therapies | ||
653 | |a checkpoint inhibitors | ||
653 | |a chemotherapy | ||
653 | |a protein kinase inhibitors | ||
653 | |a oncolytic virus | ||
653 | |a anti-cancer therapies | ||
653 | |a T cell receptor | ||
653 | |a chimeric antigen receptor (CAR) T cell (CAR-T) | ||
653 | |a signal transduction | ||
653 | |a CD8 coreceptor | ||
653 | |a signaling kinetics | ||
653 | |a oligomerization | ||
653 | |a TAM receptors | ||
653 | |a Axl | ||
653 | |a MerTK | ||
653 | |a small molecule inhibitors | ||
653 | |a CAR T cell therapy | ||
653 | |a T cell metabolism | ||
653 | |a mitochondria | ||
653 | |a memory T cell | ||
653 | |a metabolic reprogramming | ||
653 | |a adipose tissue-derived stem cells (ADSCs) | ||
653 | |a mesenchymal stem cells | ||
653 | |a myxoma virus | ||
653 | |a oncolytic virotherapy | ||
653 | |a pancreatic ductal adenocarcinoma | ||
653 | |a Flt3 | ||
653 | |a Flt3L | ||
653 | |a dendritic cells | ||
653 | |a HER2-positive | ||
653 | |a breast cancer | ||
653 | |a immune checkpoint blockade | ||
653 | |a immune checkpoint molecules | ||
653 | |a PD-1/PD-L1 | ||
653 | |a melanoma | ||
653 | |a tumour antigens | ||
653 | |a Ropporin-1 | ||
653 | |a ROPN1 | ||
653 | |a Ropporin-1B | ||
653 | |a ROPN1B | ||
653 | |a nonreplicating adenovirus vector | ||
653 | |a gene therapy | ||
653 | |a routes of delivery | ||
653 | |a virus coated with cancer cell membrane | ||
653 | |a adoptive cell transfer | ||
653 | |a targeted therapy | ||
653 | |a cell cycle | ||
653 | |a n/a | ||
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/7000 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/98947 |7 0 |z DOAB: description of the publication |